Left bundle branch pacing cuts events in OptimPacing; AI echo drafts match human reports; Impella controller recall is Class I

A bedside cardiac monitor on a short stand, its dark screen showing a single rhythm trace.

Left bundle branch pacing cut death, heart failure hospitalization or pacing-induced cardiomyopathy 59% versus right ventricular pacing in the 685-patient OptimPacing trial at the American Heart Association (AHA) Scientific Sessions.

In a randomized test, cardiologists revised AI-drafted echocardiogram reports about as often as human drafts. The Food and Drug Administration (FDA) classified the Abiomed Impella controller recall as Class I and approved asundexian, the first factor XIa inhibitor.

  • Research Nov 8, 2026
    In 685 adults with second-degree or complete atrioventricular block at 17 centers in mainland China, Hong Kong, the United Kingdom, Poland and the United States, an estimated 8.5% of the left bundle branch pacing group had the primary composite of death, heart failure hospitalization or pacing-induced cardiomyopathy at four years, versus 19.2% with right ventricular pacing, according to the American Heart Association (AHA). No patient given left bundle branch pacing developed pacing-induced cardiomyopathy, versus 11.7% with right ventricular pacing. The trial was presented Nov. 8 and published in NEJM.
  • AI Nov 9, 2026
    In the AI ECHO INSIGHT trial, which the American Heart Association (AHA) called the first randomized trial of an AI tool drafting a full echocardiogram report, cardiologists made substantial changes to 50.6% of AI-generated preliminary interpretations versus 49.7% of human drafts, meeting noninferiority. AI-assisted review averaged 4.6 minutes per echocardiogram versus 8.5 minutes without AI. The study used 1,200 previously acquired echocardiograms, was presented Nov. 9, is not peer reviewed and did not test patient outcomes, the AHA said. Healio reported it used the Echo Prime/EchoNet model.
  • FDA Nov 9, 2026
    The Food and Drug Administration (FDA) said Nov. 9 that the Abiomed Automated Impella Controller issue, first posted as an early alert, is a Class I recall. Problems include possible failure to recognize the purge cassette during setup or change, a sticking button with possible loss of console control, start-up instability and other software defects. Hospital inventory can still be used while awaiting service, and Abiomed had reported no serious injuries or deaths as of Sept. 8, according to the FDA.
    Source: FDA
  • FDA Nov 9, 2026
    The Food and Drug Administration (FDA) approved Bayer's Sunharbo (asundexian) on Nov. 9, with antiplatelet therapy, to reduce stroke risk after a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk transient ischemic attack. In the 12,327-patient OCEANIC-STROKE trial it reduced ischemic stroke risk 26% versus placebo over a median 14.2 months, with similar overall major bleeding but more gastrointestinal bleeding. The FDA said the drug is not approved for stroke prevention in atrial fibrillation.
    Source: FDA
  • Research Nov 9, 2026
    In the phase 3 trial funded by Boehringer Ingelheim and published Nov. 9 in The Lancet, the primary composite of cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, ischemia-related coronary revascularization or heart failure event occurred in 3.7% of patients given survodutide (3.6 mg or 6.0 mg weekly, pooled) and 4.1% given placebo (hazard ratio 0.89, 95% CI 0.67 to 1.18). That met noninferiority but was not a significant reduction. The authors said survodutide was not associated with increased risk for the primary end point.
    Source: The Lancet
  • AI Nov 9, 2026
    In a one-hospital South Korean study presented Nov. 9 at the American Heart Association (AHA) meeting, 2,211 adults scheduled for echocardiography had ECGs recorded on an Apple Watch and a Samsung Galaxy Watch, and the AI model distinguished people with and without left ventricular systolic dysfunction about equally well on both. Of those with consistently positive results, 81% had dysfunction confirmed by echocardiography. Study author Dr. Hak Seung Lee is chief medical officer of Medical AI Co., which developed the model; the abstract is not peer reviewed and did not test effects on treatment or outcomes, the AHA said.

The weekly innovation roundup for cardiology, published every Sunday for the week before; every item links to its sources. Latest cardiology news · All specialties

Latest news

Tagged cardiology, from the daily briefing

  1. AI reading of a routine ECG predicted dilated cardiomyopathy about as well as echocardiography across four cohorts
  2. COURAGE extended follow-up finds no difference in death or heart attack with PCI vs medical therapy
  3. Abbott wins FDA approval and CE mark for UltiSynq lead delivering conduction system pacing and defibrillation

See all the latest news